Value Proposition
· Value Proposition
The disclosed technology describes a system where scientists first use a complete gene catalog of chromosome 21 to identify candidate genes therefore enabling engineering of mice with extra copies of specific chromosome segments using embryonic stem cells. By measuring traits in these mice that mirror Down syndrome scientists can directly link genes or regions to specific developmental effects. In a commercialization context, the value lies in enabling more accurate target identification, reducing wasted R&D effort, and creating a foundation for precision medicine approaches that account for variability in disease presentation.
Unmet Need
· Clinically, Down syndrome remains a condition with no disease-modifying therapies, with care largely limited to managing symptoms such as cognitive impairment, congenital heart defects, and early-onset Alzheimer-like pathology. Scientifically, the field has been constrained for decades by the DSCR hypothesis, which assumed that a small subset of genes was responsible for most phenotypes. This created a bottleneck in identifying true therapeutic targets and limited progress in understanding disease mechanisms. The inability to experimentally isolate and test specific chromosomal regions further compounded this gap. This research addresses that unmet need by providing evidence that challenges prior assumptions and opens the door to more accurate and comprehensive models of disease biology.
Technology Description
· The core technology underpinning this research is a chromosome engineering platform that enables precise manipulation of genomic regions in mouse models. Using Cre-Lox recombination, the researchers introduced targeted duplications (trisomy) and deletions (monosomy) of the chromosomal segment corresponding to the DSCR. This was combined with embryonic stem cell engineering, fluorescence in situ hybridization (FISH), PCR validation, and quantitative phenotyping of craniofacial structures.
Stage of Development
· The study successfully demonstrates proof of concept in animal models and provides strong mechanistic insight into Down syndrome biology.
· This technology corresponds to JAX strain #005654
Data Availability
· N/A
Publication:
· Olson, L. E., Richtsmeier, J. T., Leszl, J., & Reeves, R. H. (2004). A chromosome 21 critical region does not cause specific Down syndrome phenotypes. Science, 306(5696), 687–690. https://doi.org/10.1126/science.1098992
